pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,168 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1781Endpoints1386Fierce Biotech706BioSpace698BioPharma Dive524raps234onclive165fda recalls113fda medwatch
therapy area
allOncology12303Rare Disease3214Immunology2862Cardiology2744Hematology2177Pulmonology2138Vaccines
  • AstraZeneca and GSK strike new China partnerships with Sino Biopharm
    Sino Biopharm announced two separate agreements with the United Kingdom's largest drugmakers, AstraZeneca and GSK, to deepen their presence in the Chinese market. AstraZeneca will license rights t…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • White House conducts final review of three candidates for FDA commissioner
    The White House is completing its final review of candidates to become the next Food and Drug Administration commissioner. The shortlist features Heidi Overton, a current White House adviser; Jeff…
    STAT · 4mo agoRegulatoryNeutral↗ source
← prev
page 90 of 127
next →
111
globenewswire health73
fda press59
1794
Psychiatry & CNS1204
Ophthalmology1060
Pain777
Endocrinology & Metabolism776
Nephrology760
  • U.S. officials urge pharma companies to increase domestic production of essential generic drugs
    At a private gathering in the Eisenhower Executive Office Building, senior officials from the Trump administration met with pharmaceutical leaders. Secretary of State Marco Rubio, Health Secretary…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Lung transplants boost survival for select stage 4 lung cancer patients, study finds
    Northwestern Medicine surgeons and oncologists performed double lung transplants on a small group of stage 4 lung cancer patients whose disease was confined to the lungs. The JAMA study compared 1…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Europe to Speed Review of RevMed Drug as Concerns Rise Over Kailera GLP-1 Pill and FDA Clears Vera Therapy
    European regulators said they will move more quickly to assess RevMed's investigational drug, aiming to shorten the evaluation timeline. Separate reports highlighted that recent data from Kailera'…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Prime Medicine wins arbitration over gene-editing dispute with Beam, clearing path for AATD trial
    Prime Medicine announced it had prevailed in an arbitration against Beam Therapeutics, ending a dispute over gene-editing technology. The arbitrator determined that Prime’s work on a gene-editing…
    STAT · 4mo agoRegulatoryPositive↗ source
  • FDA approves Vera Therapeutics' Trutakna for IgA nephropathy, pricing set at $425,000 per year
    The U.S. Food and Drug Administration has granted approval to Trutakna, a new therapy from Vera Therapeutics, for the treatment of IgA nephropathy. IgA nephropathy is a kidney disorder where immun…
    STAT · 4mo agoApprovalPositive↗ source
  • Arbitration panel rules Prime Medicine did not breach Beam deal over AATD therapy
    An arbitration panel has ruled that Prime Medicine did not violate its 2019 collaboration agreement with Beam Therapeutics by advancing a treatment for alpha‑1 antitrypsin deficiency (AATD). The de…
    BioPharma Dive · 4mo agoNeutral↗ source
  • ACA insurers seek median 14% premium hike for 2027 as enrollment falls
    Insurers filing with state regulators for 2027 ACA plans are asking for a median premium increase of 14%, according to an analysis of filings in 16 states and the District of Columbia. This would…
    STAT · 4mo agoRegulatoryNegative↗ source
  • FDA targets online ketamine sellers as health premiums surge, and children 2+ can now obtain CGMs without prescription
    The Food and Drug Administration is intensifying its enforcement against online retailers that sell ketamine, a controlled substance, citing concerns about unregulated distribution and public safet…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • AI licensure debate overlooks physician responsibility for patient outcomes
    The authors argue that discussions about licensing artificial intelligence tools in medicine miss the core purpose of licensure, which is accountability for clinical results. They illustrate a scen…
    STAT · 4mo agoNeutral↗ source
  • Trump administration seeks lasting overhaul of federal science policy after court setbacks
    The White House has introduced a proposal to cement its authority over federal research contracts, allowing the executive branch to direct research, end grants, and control external scientific revi…
    STAT · 4mo agoRegulatoryNegative↗ source
  • AI chatbots could provide companionship for people with dementia, but their role raises complex questions
    Jason Karlawish, a professor at the University of Pennsylvania, writes an opinion piece exploring how artificial-intelligence chatbots might be used in dementia care. He recounts the story of Doug…
    STAT · 4mo agoNeutral↗ source
  • Mass General Brigham nurses begin largest strike in Massachusetts over pay and benefits
    Thousands of nurses at Brigham and Women’s Hospital walked off the job on Wednesday, marking the first strike at the Harvard‑affiliated facility and the largest nurses walkout in the state’s histor…
    STAT · 4mo agoNegative↗ source
  • FDA clears first over-the-counter glucose monitor for children 2 and older
    The FDA cleared Dexcom's Stelo continuous glucose monitor for over-the-counter sale, allowing children age 2 and up to obtain the device without a prescription. The agency says real-time glucose d…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • RFK Jr. moves to compile list of Covid-19 vaccine injuries to streamline compensation claims
    Health secretary Robert F. Kennedy Jr. announced plans to create a list of injuries that would be presumed caused by Covid-19 vaccines. The list would allow individuals who suffer from those condi…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Longevity entrepreneur Bryan Johnson reveals he has autoimmune gastritis, a hard-to-diagnose stomach disease
    Bryan Johnson, known for his longevity ventures, announced on X that he has been diagnosed with autoimmune gastritis. The condition is a chronic inflammatory disease where antibodies attack stomac…
    STAT · 4mo agoNeutral↗ source
  • FDA greenlights Vera Therapeutics' Trutakna for IgA nephropathy
    The FDA has approved a new therapy from Vera Therapeutics aimed at treating IgA nephropathy, a chronic autoimmune kidney disorder. The drug, called Trutakna, is intended for patients with this con…
    STAT · 4mo agoApprovalPositive↗ source
  • Vertex to acquire Crinetics in $10 billion deal, expanding rare endocrine disorder pipeline
    Vertex announced on July 7, 2026 that it will acquire Crinetics Pharmaceuticals for $10 billion, marking the company’s largest-ever transaction. Crinetics is a biotech focused on developing treatm…
    STAT · 4mo agoDealNeutral↗ source
  • Vertex to acquire Crinetics in $10 billion deal, adding rare-disease drug Palsonify to its portfolio
    Vertex Pharmaceuticals announced a $10 billion transaction to purchase Crinetics Pharmaceuticals. The deal will bring Crinetics' recently launched drug Palsonify into Vertex's portfolio. Palsonify…
    STAT · 4mo agoDealPositive↗ source
  • FDA grants accelerated approval to Vera Therapeutics' Trutakna for IgA nephropathy
    The FDA has granted accelerated approval to Trutakna (formerly known as atacicept) from Vera Therapeutics for adult patients with IgA nephropathy, a chronic kidney disease that can progress to rena…
    BioPharma Dive · 4mo agoApprovalPositive↗ source
  • Vertex to buy Crinetics for $10 billion, expanding into endocrine disease drugs
    Vertex announced an agreement to acquire Crinetics Pharmaceuticals for $10 billion in cash, paying $85 per share. The purchase brings two recently launched drugs for a rare hormonal disorder into…
    BioPharma Dive · 4mo agoDealNeutral↗ source
  • Oberland invests up to $400M in MeiraGTx eye gene‑therapy pipeline
    Oberland Capital Management announced a financing package that could total $400 million to support MeiraGTx's development of gene therapies for inherited eye disorders. The arrangement includes up…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Kailera's oral GLP-1 pill shows ~10% weight loss in Chinese Phase 3 trial
    Kailera Therapeutics reported that its oral GLP-1 candidate HRS-7535 achieved about 10% average weight loss over 44 weeks in a Phase 3 study in China. The highest daily dose led to a mean 9.8% red…
    BioPharma Dive · 4mo agoPositive readoutNeutral↗ source
  • STAT newsletter highlights the decline of employer-based health insurance in the U.S.
    John Wilkerson, a Washington correspondent for STAT, writes the D.C. Diagnosis newsletter that focuses on health policy. In this edition he turns his attention to the weakening of the employer-base…
    STAT · 4mo agoNegative↗ source